Zimmer Partners LP bought a new stake in Immunocore Holdings plc (NASDAQ:IMCR) during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 10,000 shares of the company’s stock, valued at approximately $426,000.
Other hedge funds also recently made changes to their positions in the company. Laurion Capital Management LP purchased a new position in shares of Immunocore in the 1st quarter valued at approximately $213,000. Victory Capital Management Inc. purchased a new position in shares of Immunocore in the 1st quarter valued at approximately $426,000. UBS Group AG purchased a new position in shares of Immunocore in the 1st quarter valued at approximately $497,000. Caas Capital Management LP purchased a new position in shares of Immunocore in the 1st quarter valued at approximately $639,000. Finally, Morgan Stanley acquired a new stake in shares of Immunocore in the 1st quarter valued at approximately $648,000. Institutional investors own 35.17% of the company’s stock.
Separately, Zacks Investment Research cut Immunocore from a “hold” rating to a “sell” rating in a report on Wednesday, May 26th.
Immunocore (NASDAQ:IMCR) last posted its quarterly earnings results on Wednesday, May 12th. The company reported ($1.05) EPS for the quarter, missing the consensus estimate of ($0.92) by ($0.13). The firm had revenue of $11.41 million during the quarter, compared to analyst estimates of $8.38 million. Research analysts anticipate that Immunocore Holdings plc will post -4.14 EPS for the current year.
Immunocore Company Profile
Immunocore Holdings Limited, a late-stage biotechnology company, develops immunotherapies for the treatment of oncology, infectious, and autoimmune diseases. The company's lead oncology therapeutic candidate is tebentafusp, which is in a randomized Phase III clinical trial in patients with previously untreated metastatic uveal melanoma, a cancer that has historically proven to be insensitive to other immunotherapies.
Read More: Do You Need a Fiduciary?
Receive News & Ratings for Immunocore Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunocore and related companies with MarketBeat.com's FREE daily email newsletter.